Related Experiment Video
Updated: Aug 26, 2025

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Ritonavir Form III: A New Polymorph After 24 Years
Xin Yao1, Rodger F Henry2, Geoff G Z Zhang3
1School of Pharmacy, University of Wisconsin-Madison, Madison, WI 53705, USA; Development Sciences, Research and Development, AbbVie Inc., North Chicago, IL 60064, USA.
Abstract:
Polymorphism occurs widely in pharmaceutical solids, and must be thoroughly studied during product development. Twenty-four years after ritonavir (RTV) Form II materialized, we report a new polymorph, Form III, discovered via melt crystallization. Form III has a unique PXRD pattern, Raman spectrum, lower melting point and heat of fusion, compared to the known polymorphs, Form I and Form II. It is the least stable form, monotropically, among the three polymorphs. Form III differs from Form I and Form II in molecular conformation and hydrogen bonding motifs in crystal lattice. Nucleation from RTV supercooled liquid is slow, and selected Form III exclusively. The discovery of RTV Form III demonstrates the importance of crystal nucleation studies. Crystallization from supercooled liquids should be incorporated as part of polymorph screening workflow.
Related Concept Videos
Retrovirus Life Cycles
Retroviruses
Size and Structure of Viral Genomes

